北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 2025 年第三次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 E United Sales PT YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海三友医疗器械股份有限公司 北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 嘉源(2025)-04-514 北京市嘉源律师事务所(以下简称"本所")接受上海三友医疗器械股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《上 海三友医疗器械股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第三次临时股东大会(以下简称"本次股东大会")进 行见证,并依法出具本法律意见书。 为出具本法律意见书,本 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：688085 证券简称：三友医疗 公告编号：2025-048 上海三友医疗器械股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 上海三友医疗器械股份有限公司（以下简称"公司"）的全资孙公司北京水 木天蓬医疗设备有限公司于近期收到政府补助 331.00 万元，占公司 2024 年度经 审计归属上市公司净利润的比例为 28.86%。上述政府补助属于与收益相关的政 府补助。 二、补助的类型及对公司的影响 公司根据《企业会计准则第 16 号——政府补助》等相关规定，确认上述事 项并划分补助类型。上述政府补助未经审计，具体的会计处理以及对公司相关年 度损益的影响情况最终以审计机构年度审计确认后的结果为准。敬请广大投资者 注意投资风险。 特此公告。 上海三友医疗器械股份有限公司董事会 2025 年 7 月 1 日 ...

Group 1 - The core point of the news is that the main funds in the Shanghai and Shenzhen markets experienced a net inflow of 7.138 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 323 million yuan [1] - A total of 233 stocks saw net inflows, while 355 stocks experienced net outflows [1] - On the Sci-Tech Innovation Board, 452 stocks rose, with one stock, Tai Lingwei, hitting the daily limit, while 126 stocks declined [1] Group 2 - The top three stocks with the highest net inflow of main funds are: Han's Laser with 362 million yuan, SMIC with 349 million yuan, and Tai Lingwei with 107 million yuan [2] - The stock with the highest net outflow was Guangda Special Materials, which saw a net outflow of 158 million yuan despite a price increase of 2.91% [1][2] - There are 62 stocks that have seen continuous net inflows for more than three trading days, with Sanyou Medical leading at 10 consecutive days [2] Group 3 - The main funds' inflow ranking shows that Han's Laser had an inflow rate of 6.40% and a price increase of 0.64% [2] - Other notable stocks include Kingsoft Office with an inflow of 101 million yuan and a price increase of 3.87%, and Wealth Trend with an inflow of 100 million yuan and a price increase of 17.84% [2] - A total of 114 stocks experienced continuous net outflows, with Bohui Technology leading at 24 consecutive days of outflow [2]

Group 1 - The stock of Sanyou Medical (688085) has a comprehensive score of 43.15, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 18.74 yuan, with a 5-day main cost of 18.44 yuan and a 20-day main cost of 19.31 yuan [1] - There have been no instances of the stock hitting the upper limit in the past year, and it has also not hit the lower limit [1] Group 2 - The short-term pressure level is at 18.73 yuan, while the short-term support level is at 18.05 yuan [2] - The stock price has broken through the short-term pressure level, indicating a potential short-term strength, although the medium-term trend remains unclear [2] - The funds flow data for June 25, 2025, shows a net outflow of 17.43 million yuan from main funds, with retail investors experiencing a net outflow of 4.39 million yuan [2]

二 O 二五年七月 上海三友医疗器械股份有限公司 证券代码：688085 证券简称：三友医疗 上海三友医疗器械股份有限公司 $$\bigtriangleup_{\mathbb{Z}}\!\!\!\bigvee_{\mathbb{R}}\!\!\!\bigvee_{\mathbb{R}}\!\!\!\bigtriangleup_{\mathbb{R}}\!\!\!\bigtriangleup_{\mathbb{R}}$$ 上海三友医疗器械股份有限公司 上海三友医疗器械股份有限公司 上海三友医疗器械股份有限公司 上海三友医疗器械股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 大会规则》以及《上海三友医疗器械股份有限公司章程》《上海三友医疗器械股份有限 公司股东大会议事规则》等相关规定，上海三友医疗器械股份有限公司（以下简称"公 司"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将 对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二 ...

上海三友医疗器械股份有限公司 证券代码：688085 证券简称：三友医疗 上海三友医疗器械股份有限公司 2025 年第三次临时股东大会 会议资料 二 O 二五年七月 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等权利。股 东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司和其他股东及股东 代理人的合法权益，不得扰乱股东大会的正常秩序。 | 2025 年第三次临时股东大会会议须知 2 | | --- | | 2025 年第三次临时股东大会会议议程 4 | | 议案一 7 | | 关于取消监事会、监事及修订《公司章程》并办理工商登记的议案 7 | | 议案二 9 | | 关于修订部分公司治理制度的议案 9 | | 议案三 11 | | 关于公司董事会换届选举暨提名第四届董事会非独立董事的议案 11 | | 议案四 12 | | 关于公司董事会换届选举暨提名第四届董事会独立董事的议案 12 | 上海三友医疗器械股份有限公司 上海三友医疗器械股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-045 上海三友医疗器械股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年7月4日 至2025 年 7 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类型 序号 议案名称 A 股股东 非累积投票议案 理工商登记的议案》 累积投票议案 非独立董事的议案》 公司第四届董事会非 ...

Core Viewpoint - The document outlines the information disclosure management system of Shanghai Sanyou Medical Co., Ltd., emphasizing the importance of timely, accurate, and complete disclosure of significant information that may impact stock trading prices and investment decisions [1][2]. Group 1: Information Disclosure Principles - Information disclosure is a continuous responsibility of the company, requiring adherence to laws, regulations, and stock exchange rules [9][10]. - The company must ensure that all disclosed information is true, accurate, complete, and timely, allowing equal access for all investors [10][16]. - Disclosure documents should be clear, concise, and free from misleading statements or omissions [8][9]. Group 2: Types of Disclosable Information - Significant information includes financial performance, profit forecasts, mergers and acquisitions, major investments, and legal matters [3][4]. - The company must disclose any information that could significantly affect stock prices or investment decisions, including major contracts and government approvals [2][3]. - Information related to stock issuance, repurchase, and incentive plans must also be disclosed [3][4]. Group 3: Disclosure Procedures - The board of directors is responsible for overseeing the information disclosure process, with the secretary of the board coordinating the specific activities [57][58]. - All disclosures must be submitted to the Shanghai Stock Exchange and made available to the public [4][10]. - The company must correct any previously disclosed information that is found to be erroneous or misleading [64]. Group 4: Responsibilities of Disclosure Obligors - The chairman of the board is the ultimate responsible person for information disclosure, and all relevant parties must comply with disclosure obligations [7][10]. - Individuals involved in the disclosure process must ensure that the information is kept confidential until officially disclosed [10][11]. - The company must maintain a record of insider information and ensure that insider trading does not occur [32][34].

上海三友医疗器械股份有限公司 内部审计制度 上海三友医疗器械股份有限公司 内部审计制度 第一章 总则 本制度所称内部控制，是指公司董事会、高级管理人员及其他有关人员实 施的、旨在实现控制目标的过程。内部控制的目标是合理保证公司经营管 理合法合规、资产安全、财务报告及相关信息真实完整，提高经营效率和 效果，促进企业实现发展战略。 本制度旨在明确内部审计工作的领导体制、职责权限、人员配备、经费保 障、审计结果运用和责任追究等。 内部审计部门对董事会负责，向审计委员会报告工作。审计部在监督检查 上海三友医疗器械股份有限公司 内部审计制度 审计工作情况和发现的问题，并在年度和半年度结束后向审计委员会提交 内部审计工作报告。内部审计人员对于检查中发现的内部控制缺陷及实施 中存在的问题，应如实在内部审计工作报告中反映，并在向审计委员会报 告后进行追踪，确定相关部门已及时采取适当的改进措施。 过程中，应当接受审计委员会的监督指导。审计部发现公司重大问题或线 索，应当立即向审计委员会直接报告。 董事会审计委员会应： 内部审计部门应当保持独立性，不得置于财务部门的领导之下，或者与财 务部门合署办公。内部审计部门和内部审计人员不 ...